FDA Halts 23andMe Personal Genetic Tests
By Marcy Darnovsky; Jessica Cussins,
Medical Laboratory Observer
| 03. 10. 2014
Direct-to-consumer (DTC) genetic testing gained notoriety in the autumn of 2008. That was when two prestigious publications, The New Yorker and The New York Times, featured largely positive accounts of a celebrity “spit party”—at which notables dressed in cocktail attire ejected their saliva into test tubes for genetic analysis.1,2
That trendy gathering seemed to be the leading edge of a new era of personalized medicine. Companies selling saliva kits online promised that the tests would give customers medically crucial information about risks for a wide range of diseases. Some observers enthused that DTC gene tests would revolutionize medical care.
But at least to date, the reality has fallen far short of such claims.
One major setback for the DTC gene test industry came in 2010, when the Government Accountability Office (GAO) issued a stinging report3 after it had submitted identical DNA samples to four DTC gene testing companies and gotten back contradictory results. The GAO’s report called DTC gene tests “misleading and of little or no practical use.” The same year, when Pathway Genomics tried to sell a DTC...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...